Swedish biotech Lokon Pharma, currently developing LOAd703, a potent double-armed (TMZ-CD40L/4-1BBL) oncolytic adenovirus for solid tumors, has announced a collaboration with Swiss pharma giant, Roche (ROG: SIX).
The combination of LOAd703 and Roche’s anti-PD-L1 checkpoint antibody, Tecentriq (atezolizumab), will be tested in pancreatic cancer and melanoma.
An ongoing Phase I/IIa study (LOKON001) at Baylor College of Medicine, Houston, for patients with advanced pancreatic cancer, will be expanded to include Tecentriq.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze